The RETROGEN Inc. Laboratories of the United States, a company with more than 20 years leading the research of the Human Genetic Code, has been authorized by the FDA to provide the service of the Pharmaceutical Evaluation of patients, through its product» PGxINSIGHT «, which can predict a patient’s response to treatment with almost 100 drug types to control diseases related to cardiovascular, chronic pain, or psychiatric problems.


BIOADVANCE CENTROAMERICA S.A. Is the representative for Latin America of this prestigious company, and offers with this video a simple explanation on the Pharmacological Optimization Program – POF, and on the scope of the diagnostic test, which is already available for Costa Rica, Colombia and Nicaragua.

More information on: